健择单药联合伽玛刀治疗18例晚期胰腺癌疗效观察重点.docVIP

健择单药联合伽玛刀治疗18例晚期胰腺癌疗效观察重点 健择单药联合伽玛刀治疗18例晚期胰腺癌疗效观察重点 PAGE / NUMPAGES 健择单药联合伽玛刀治疗18例晚期胰腺癌疗效观察重点 健择单药联合伽玛刀治疗 18 例晚期胰腺癌疗效观察 健择单药联合伽玛刀治疗 18 例晚期胰腺癌疗效观察 2008-5-9 11:43:34 作者：潘德键 ，王标，周锡建，王东林，李相勇， 范晓强，周仁贵，唐新宇 【摘要】 ［目的］ 观察健择单药联合伽玛刀治疗不能手术胰腺癌的疗效。［方法］ 18 例晚期胰腺癌患者均采用健择 1000mg/m2，第 1、8 天静脉输注， 21 天为 1 个周期，治疗 6 个周期。第 1 个周期化疗的第 2 天行伽玛刀治疗，等剂量曲线为 55%～70%，肿瘤≤ 5cm的单次周边剂量 4.0Gy～5.5Gy，肿瘤＞ 5cm 的单次周边剂量 3.0Gy～4.0Gy，治疗总剂量为 32Gy～48Gy，治疗次数 8～ 12 次， 6 次/ 周。［结果］ 全组 18 例共完成 96 个周期化疗， 3 个月 CT检查， CR 3 例 (17%)，PR 4 例(22%)，NC 10 例(56%)， PD 1 例(5%)，中位生存期 11.8 个 月，临床受益反应 17/18 (94%) 。主要毒副反应是白细胞、血小板下降。论］ 健择单药联合伽玛刀治疗不能手术的晚期胰腺癌具有较好的耐受性和疗效。  ［结 【关键词】 胰腺肿瘤 Efficacy of Gemcitabine Combined with Gamma Rays Radiotherapy for 18 Cases with Advanced Pancreatic Cancer Abstract: ［Purpose］ To investigate the efficacy of gemcitabine combined with gamma rays radiotherapy for treatment of unresectable pancreatic cancer. ［ Methods］ Intravenous infusions of gemcitabine at dose of 1000mg/m2 was given at day 1, 8 for six cycles (21 days per cycle) in 18 cases with advanced pancreatic cancer. All patients were treated with gamma rays radiotherapy from the second day in the first cycle of chemotherapy. Dose curve of these cases was 55%～ 70%. Encircled dose for carcinoma less than or equal to 5cm was 4.0 ～ 5.5Gy per fraction, and that for carcinoma greater than 5cm was 3.0 ～ 4.0Gy per fraction. The range of total dose was 32 ～ 48Gy in 8 ～ 12 fractions and 6 fractions per week. ［Results ］ Eigheen cases in the series received 96 cycles of chemotherapy. Examined by CT after 3 months, there were 3 cases CR (17%), 4 cases PR (22%), 10 cases NC (56%) and 1 case PD (5%). The median survival was 11.8 months. Clinical benefit response (CBR) was 17/18 (94%). The main toxicity revealed neutropenia and thrombocytopenia. ［Conclusion ］ Gemcitabine combined with gamma rays radiotherapy is feasible and effective for treatment of unresectable advanced pancreatic cancer. Key words: gemcitabine; gamma rays; pancreatic neoplasms 胰腺癌为消化系统的较常见恶性肿瘤，